GLP-1 Market Insights: Key Highlights, Market Expansion & Future Demand 2035

GLP-1 receptor agonist market have captured the attention of both large and small pharmaceutical companies, for more than a decade. However, after a decade-long dribble of GLP-1 drugs and the recent approval of obesity drugs, the domain has gained significant attention.

The global GLP-1 market is expected to grow from USD 101.4 billion in 2026 to USD 180 billion by 2035, at a CAGR of 8.7% during the forecast period, till 2035.

Various firms in the glp-1 domain are increasingly entering into collaborations with local and internal players to expand their capabilities, leverage complementary expertise and access new markets.

The rising interest in the GLP-1 domain is reflected in the wide array of partnerships established between various stakeholders in the recent past. Around 50% of the partnerships were signed before post 2022; of these, majority (more than 40%) were licensing agreement. This is followed by agreements signed in 2021 and 2022 (18%, each).

In terms of intercontinental, most of the deals have been inked by players based in North America. Further, the majority of the players based in North America have signed intercontinental agreements with the stakeholders headquartered in Asia-Pacific and Rest of the world (nine).

Around 60% of the GLP-1 drug candidates are currently being evaluated in clinical stages of development; of these, most of the candidates target metabolic disorders, such as Type 2 diabetes and obesity. Notably, 11% GLP-1 drugs candidates are approved by various regulatory body across the globe.

Examples of GLP-1 drug (Tri-agonist)

• DR10624 (Doer Biologics)
• Efocipegtrutide, HM15211 (Hanmi Pharmaceutical)
• HM15275 (Hanmi Pharmaceutical)
• MWN101 (Shanghai Minwei Biotechnology)
• Retatrutide, LY3437943 (Eli Lilly)
• UBT251 (United Bio-Technology)

Leading Drug Developers

• Boehringer Ingelheim
• Eli Lilly
• Novo Nordisk
• Other Developers

Key Companies Profiled

• AstraZeneca
• Biolingus
• Boehringer Ingelheim
• D&D Pharmatech
• Eli Lilly
• Gmax Biopharm
• Hanmi Pharmaceutical
• Innogen
• Novo Nordisk
• PegBio
• Pfizer
• QL Biopharma
• Roche
• Sanofi
• Sciwind Biosciences
• Tonghua Dongbao Pharmaceutical
• Viking Therapeutics
• Vivani
• vTv Therapeutic

The latest research report specializes in the in-depth analysis of the macroeconomic and microeconomic factors affecting the GLP-1 Market development. The report also concentrates on the regulatory framework that is shaping the future of the global market. New and existing pricing structures, emerging application areas, and upcoming investment opportunities have also been detailed in the report. The report further studies the projected growth factors that are expected to influence the market dynamics over the forecast timeframe.

The study is inclusive of a comprehensive analysis of the commonly used marketing and promotional strategies adopted by the key market players. Taking into account the existing market development factors, historical events, and recent market trends, the study presents a balanced opinion on the future scenario of the GLP-1 Market. It thus supports its opinion by discussing the key corporate strategies, such as mergers & acquisitions, takeovers, joint ventures, and strategic alliances, used by the market players to strengthen their global footprint.

Research Methodology

Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the GLP-1 Market.

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.

Read more: https://www.rootsanalysis.com/reports/glp-1-market.html